⏱ 1 min read
Background
Founded in 2002 in Geneva, Addex Therapeutics is a clinical-stage biotech. It develops small-molecule allosteric modulators for neurological disorders.
The key points
Addex Therapeutics has raised 2.8 million dollars in gross proceeds through its at-the-market programme with US bank H.C. Wainwright. The sale extends its cash runway into the fourth quarter of 2027.
Its lead candidate, dipraglurant, targets recovery after brain injury, including stroke and traumatic brain injury.
Key figures
- Amount raised: 2.8 million dollars gross.
- Programme ceiling, raised in December 2025: 3.3 million dollars.
- H.C. Wainwright commission: 3% of gross proceeds.
- Shares issued: just over 218.5 million.
What it means for businesses
Addex has sold 437,869 American depositary shares, representing more than 52 million ordinary shares. Shares in circulation now exceed 210 million.
What's next
Beyond its own pipeline, Addex launched the Geneva spin-off Neurosterix and led an investment in Stalicla.
